Chronic obstructive pulmonary disease and cardiac diseases an urgent need for integrated care

American Journal of Respiratory and Critical Care Medicine

Volumn 194, Issue 11, 2016, Pages 1319-1336

  Roversi, Sara ^a   Fabbri, Leonardo M ^a   Sin, Don D ^b   Hawkins, Nathaniel M ^b   Agustí, Alvar ^c  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Aging; Comorbidities; Dyspnea; Metabolic syndrome; Smoking

Indexed keywords

ACLIDINIUM BROMIDE; AMIODARONE; BISOPROLOL; CARVEDILOL; GLYCOPYRRONIUM; IPRATROPIUM BROMIDE; METOPROLOL SUCCINATE; NEBIVOLOL; PROPAFENONE; SACUBITRIL; SOTALOL; TIOTROPIUM BROMIDE; UMECLIDINIUM; VALSARTAN;

ACUTE HEART FAILURE; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DAILY LIFE ACTIVITY; DIFFERENTIAL DIAGNOSIS; DYSPNEA; ECHOCARDIOGRAPHY; EXERCISE; FATIGUE; HEART ARRHYTHMIA; HEART DISEASE; HEART RIGHT VENTRICLE FAILURE; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; LUNG EMBOLISM; MEDLINE; NUTRITIONAL SUPPORT; PATIENT EDUCATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SPIROMETRY; TREATMENT INDICATION; COMPLICATION; HEART DISEASES; INTEGRATED HEALTH CARE SYSTEM; PROCEDURES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

DELIVERY OF HEALTH CARE, INTEGRATED; HEART DISEASES; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 85002670293     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201604-0690SO     Document Type: Article

References (230)

1. Vos T, Barber RM, Bell B, Bertozzi-Villa A, Biryukov S, Bolliger I, Charlson F, Davis A, Degenhardt L, Dicker D, et al.; Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;386:743-800.
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. 2016 [accessed 2016 Feb. 7]. Available from: http://www.goldcopd.org
3. Regan EA, Lynch DA, Curran-Everett D, Curtis JL, Austin JH, Grenier PA, Kauczor HU, Bailey WC, DeMeo DL, Casaburi RH, et al.; Genetic Epidemiology of COPD (COPDGene) Investigators. Clinical and radiologic disease in smokers with normal spirometry. JAMA Intern Med 2015;175:1539-1549.
4. Woodruff PG, Barr RG, Bleecker E, Christenson SA, Couper D, Curtis JL, Gouskova NA, Hansel NN, Hoffman EA, Kanner RE, et al.; SPIROMICS Research Group. Clinical significance of symptoms in smokers with preserved pulmonary function. N Engl J Med 2016;374:1811-1821.
5. National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. The health consequences of smoking-50 years of progress: a report of the Surgeon General. 2014 [accessed 2016 Jul. 11]. Available from: http://www.ncbi.nlm.nih. gov/books/NBK179276
6. Vanfleteren L E GW, Spruit MA, Groenen M, Gaffron S, Van Empel V P M, Bruijnzeel P L B, Rutten E P A, Op't Roodt J, Wouters E F M, Franssen F M E. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187:728-735.
7. Müllerova H, Agusti A, Erqou S, Mapel DW. Cardiovascular comorbidity in COPD: systematic literature review. Chest 2013;144:1163-1178.
8. Agarwal SK, Heiss G, Barr RG, Chang PP, Loehr LR, Chambless LE, Shahar E, Kitzman DW, Rosamond WD. Airflow obstruction, lung function, and risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC) study. Eur J Heart Fail 2012;14:414-422.
9. Wannamethee SG, Shaper AG, Papacosta O, Lennon L, Welsh P, Whincup PH. Lung function and airway obstruction: associations with circulating markers of cardiac function and incident heart failure in older men-the British Regional Heart Study. Thorax 2016;71:526-534.
10. 1: a new risk factor for coronary heart disease mortality. Am J Respir Crit Care Med 1995;151:390-398.
11. Li J, Agarwal SK, Alonso A, Blecker S, Chamberlain AM, London SJ, Loehr LR, McNeill AM, Poole C, Soliman EZ, et al. Airflow obstruction, lung function, and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2014;129:971-980.
12. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004;351:2599-2610.
13. Gan WQ, Man S F P, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574-580.
14. Patel A R C, Kowlessar BS, Donaldson GC, Mackay AJ, Singh R, George SN, Garcha DS, Wedzicha JA, Hurst JR. Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;188:1091-1099.
15. Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med 2015;3:631-639.
16. Almagro P, López García F, Cabrera F, Montero L, Morchón D, Díez J, Soriano J; Grupo Epoc De La Sociedad Española De Medicina Interna. Comorbidity and gender-related differences in patients hospitalized for COPD: the ECCO study. Respir Med 2010;104:253-259.
17. Antonelli-Incalzi R, Imperiale C, Bellia V, Catalano F, Scichilone N, Pistelli R, Rengo F; SaRA Investigators. Do GOLD stages of COPD severity really correspond to differences in health status? Eur Respir J 2003;22:444-449.
18. Barr RG, Celli BR, Mannino DM, Petty T, Rennard SI, Sciurba FC, Stoller JK, Thomashow BM, Turino GM. Comorbidities, patient knowledge, and disease management in a national sample of patients with COPD. Am J Med 2009;122:348-355.
19. Baty F, Putora PM, Isenring B, Blum T, Brutsche M. Comorbidities and burden of COPD: a population based case-control study. Plos One 2013;8:e63285.
20. Blanchette CM, Roberts MH, Petersen H, Dalal AA, Mapel DW. Economic burden of chronic bronchitis in the United States: a retrospective case-control study. Int J Chron Obstruct Pulmon Dis 2011;6:73-81.
21. Cazzola M, Calzetta L, Bettoncelli G, Cricelli C, Romeo F, Matera MG, Rogliani P. Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study. Respir Med 2012;106:249-256.
22. Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring E Jr, She D. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006;16:63-70.
23. Chen Y, Li Q, Johansen H. Age and sex variations in hospital readmissions for COPD associated with overall and cardiac comorbidity. Int J Tuberc Lung Dis 2009;13:394-399.
24. Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis 2009;4:337-349.
25. García Rodríguez LA, Wallander M-A, Tolosa LB, Johansson S. Chronic obstructive pulmonary disease in UK primary care: incidence and risk factors. COPD 2009;6:369-379.
26. Holguin F, Folch E, Redd SC, Mannino DM. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 2005;128:2005-2011.
27. Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005;128:2640-2646.
28. Kollert F, Müller C, Tippelt A, Jörres RA, Heidinger D, Probst C, Pfeifer M, Budweiser S. Anaemia in chronic respiratory failure. Int J Clin Pract 2011;65:479-486.
29. Konecny T, Park JY, Somers KR, Konecny D, Orban M, Soucek F, Parker KO, Scanlon PD, Asirvatham SJ, Brady PA, et al. Relation of chronic obstructive pulmonary disease to atrial and ventricular arrhythmias. Am J Cardiol 2014;114:272-277.
30. Lange P, Mogelvang R, Marott JL, Vestbo J, Jensen JS. Cardiovascular morbidity in COPD: a study of the general population. COPD 2010;7:5-10.
31. Lin P-J, Shaya FT, Scharf SM. Economic implications of comorbid conditions among Medicaid beneficiaries with COPD. Respir Med 2010;104:697-704.
32. Mapel DW, Dedrick D, Davis K. Trends and cardiovascular comorbidities of COPD patients in the Veterans Administration Medical System, 1991-1999. COPD 2005;2:35-41.
33. Miller J, Edwards LD, Agustí A, Bakke P, Calverley P M A, Celli B, Coxson HO, Crim C, Lomas DA, Miller BE, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 2013;107:1376-1384.
34. Miniati M, Monti S, Pavlickova I, Bottai M. Survival in COPD: impact of lung dysfunction and comorbidities. Medicine (Baltimore) 2014;93:e76.
35. Schneider C, Bothner U, Jick SS, Meier CR. Chronic obstructive pulmonary disease and the risk of cardiovascular diseases. Eur J Epidemiol 2010;25:253-260.
36. Sidney S, Sorel M, Quesenberry CP Jr, DeLuise C, Lanes S, Eisner MD. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005;128:2068-2075.
37. Sin DD, Man S F P. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003;107:1514-1519.
38. Sode BF, Dahl M, Nordestgaard BG. Myocardial infarction and other co-morbidities in patients with chronic obstructive pulmonary disease: a Danish nationwide study of 7.4 million individuals. Eur Heart J 2011;32:2365-2375.
39. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J 2006;28:1245-1257.
40. Boudestein L C M, Rutten FH, Cramer MJ, Lammers J W J, Hoes AW. The impact of concurrent heart failure on prognosis in patients with chronic obstructive pulmonary disease. Eur J Heart Fail 2009;11:1182-1188.
41. Rothnie KJ, Smeeth L, Herrett E, Pearce N, Hemingway H, Wedzicha J, Timmis A, Quint JK. Closing the mortality gap after a myocardial infarction in people with and without chronic obstructive pulmonary disease. Heart 2015;101:1103-1110.
42. Sachdev M, Sun JL, Tsiatis AA, Nelson CL, Mark DB, Jollis JG. The prognostic importance of comorbidity for mortality in patients with stable coronary artery disease. J Am Coll Cardiol 2004;43:576-582.
43. Andersson T, Magnuson A, Bryngelsson I-L, Frøbert O, Henriksson KM, Edvardsson N, Poçi D. All-cause mortality in 272, 186 patients hospitalized with incident atrial fibrillation 1995-2008: a Swedish nationwide long-term case-control study. Eur Heart J 2013;34:1061-1067.
44. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland J G F, Coats A J S, Falk V, González-Juanatey JR, Harjola V-P, Jankowska EA, et al.; Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-2200.
45. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos G, Fonarow GC, Givertz MM, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2016;134:e282-293.
46. Mentz RJ, Kelly JP, Von Lueder TG, Voors AA, Lam C S P, Cowie MR, Kjeldsen K, Jankowska EA, Atar D, Butler J, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol 2014;64:2281-2293.
47. Kwon B-J, Kim D-B, Jang S-W, Yoo K-D, Moon K-W, Shim BJ, Ahn S-H, Cho E-J, Rho T-H, Kim J-H. Prognosis of heart failure patients with reduced and preserved ejection fraction and coexistent chronic obstructive pulmonary disease. Eur J Heart Fail 2010;12:1339-1344.
48. Rushton CA, Satchithananda DK, Jones PW, Kadam UT. Noncardiovascular comorbidity, severity and prognosis in non-selected heart failure populations: a systematic review and meta-analysis. Int J Cardiol 2015;196:98-106.
49. De Blois J, Simard S, Atar D, Agewall S; Norwegian Heart Failure Registry. COPD predicts mortality in HF: the Norwegian Heart Failure Registry. J Card Fail 2010;16:225-229.
50. Guazzi M, Myers J, Vicenzi M, Bensimhon D, Chase P, Pinkstaff S, Arena R. Cardiopulmonary exercise testing characteristics in heart failure patients with and without concomitant chronic obstructive pulmonary disease. Am Heart J 2010;160:900-905.
51. Tavazzi L, Swedberg K, Komajda M, Böhm M, Borer JS, Lainscak M, Robertson M, Ford I; SHIFT Investigators. Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study. Int J Cardiol 2013;170:182-188.
52. Yoshihisa A, Takiguchi M, Shimizu T, Nakamura Y, Yamauchi H, Iwaya S, Owada T, Miyata M, Abe S, Sato T, et al. Cardiovascular function and prognosis of patients with heart failure coexistent with chronic obstructive pulmonary disease. J Cardiol 2014;64:256-264.
53. Mentz RJ, Schulte PJ, Fleg JL, Fiuzat M, Kraus WE, Piña IL, Keteyian SJ, Kitzman DW, Whellan DJ, Ellis SJ, et al. Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION). Am Heart J 2013;165:193-199.
54. Dal Negro RW, Bonadiman L, Turco P. Prevalence of different comorbidities in COPD patients by gender and GOLD stage. Multidiscip Respir Med 2015;10:24.
55. Divo MJ, Casanova C, Marin JM, Pinto-Plata VM, De-Torres JP, Zulueta JJ, Cabrera C, Zagaceta J, Sanchez-Salcedo P, Berto J, et al.; BODE Collaborative Group. COPD comorbidities network. Eur Respir J 2015;46:640-650.
56. Rutten FH, Moons K G M, Cramer M-JM, Grobbee DE, Zuithoff N P A, Lammers J-WJ, Hoes AW. Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. BMJ 2005;331:1379.
57. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet 2007;370:786-796.
58. Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola V-P, Hochadel M, Komajda M, Lassus J, Lopez-Sendon JL, et al.; EuroHeart Survey Investigators; Heart Failure Association, European Society of Cardiology. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006;27:2725-2736.
59. MacDonald MI, Shafuddin E, King PT, Chang CL, Bardin PG, Hancox RJ. Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease. Lancet Respir Med 2016;4:138-148.
60. McAllister DA, Maclay JD, Mills NL, Leitch A, Reid P, Carruthers R, O'Connor J, McAlpine L, Chalmers G, Newby DE, et al. Diagnosis of myocardial infarction following hospitalisation for exacerbation of COPD. Eur Respir J 2012;39:1097-1103.
61. Parissis JT, Andreoli C, Kadoglou N, Ikonomidis I, Farmakis D, Dimopoulou I, Iliodromitis E, Anastasiou-Nana M, Lainscak M, Ambrosio G, et al. Differences in clinical characteristics, management and short-term outcome between acute heart failure patients chronic obstructive pulmonary disease and those without this co-morbidity. Clin Res Cardiol 2014;103:733-741.
62. Fisher KA, Stefan MS, Darling C, Lessard D, Goldberg RJ. Impact of COPD on the mortality and treatment of patients hospitalized with acute decompensated heart failure: the Worcester Heart Failure Study. Chest 2015;147:637-645.
63. Wakabayashi K, Sato N, Kajimoto K, Minami Y, Mizuno M, Keida T, Asai K, Munakata R, Murai K, Sakata Y, et al.; ATTEND investigators. Incidence and predictors of in-hospital non-cardiac death in patients with acute heart failure. Eur Heart J Acute Cardiovasc Care [online ahead of print] 2 Jul. 2015; DOI: 10.1177/2048872615593388.
64. Lainscak M, Hodoscek LM, Düngen H-D, Rauchhaus M, Doehner W, Anker SD, Von Haehling S. The burden of chronic obstructive pulmonary disease in patients hospitalized with heart failure. Wien Klin Wochenschr 2009;121:309-313.
65. Matamis D, Tsagourias M, Papathanasiou A, Sineffaki H, Lepida D, Galiatsou E, Nakos G. Targeting occult heart failure in intensive care unit patients with acute chronic obstructive pulmonary disease exacerbation: effect on outcome and quality of life. J Crit Care 2014;29:315.e7-315.e14.
66. Abroug F, Ouanes-Besbes L, Nciri N, Sellami N, Addad F, Hamda KB, Amor AB, Najjar MF, Knani J. Association of left-heart dysfunction with severe exacerbation of chronic obstructive pulmonary disease: diagnostic performance of cardiac biomarkers. Am J Respir Crit Care Med 2006;174:990-996.
67. Yu T-C, Zhou H, Suh K, Arcona S. Assessing the importance of predictors in unplanned hospital readmissions for chronic obstructive pulmonary disease. Clinicoecon Outcomes Res 2015;7:37-51.
68. Minasian AG, Van Den Elshout FJ, Dekhuijzen PR, Vos PJ, Willems FF, Van Den Bergh PJ, Heijdra YF. Serial pulmonary function tests to diagnose COPD in chronic heart failure. Transl Respir Med 2014;2:12.
69. Güder G, Brenner S, Störk S, Hoes A, Rutten FH. Chronic obstructive pulmonary disease in heart failure: accurate diagnosis and treatment. Eur J Heart Fail 2014;16:1273-1282.
70. Brenner S, Güder G, Berliner D, Deubner N, Fröhlich K, Ertl G, Jany B, Angermann CE, Störk S. Airway obstruction in systolic heart failure-COPD or congestion? Int J Cardiol 2013;168:1910-1916.
71. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013;128:1810-1852.
72. Roberts E, Ludman AJ, Dworzynski K, Al-Mohammad A, Cowie MR, McMurray J J V, Mant J; NICE Guideline Development Group for Acute Heart Failure. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic metaanalysis in the acute care setting. BMJ 2015;350:h910.
73. Hawkins NM, Virani S, Ceconi C. Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services. Eur Heart J 2013;34:2795-2803.
74. Sacks CA, Jarcho JA, Curfman GD. Paradigm shifts in heart-failure therapy-a timeline. N Engl J Med 2014;371:989-991.
75. Suzuki T, Lyon A, Saggar R, Heaney LM, Aizawa K, Cittadini A, Mauro C, Citro R, Limongelli G, Ferrara F, et al. Biomarkers of acute cardiovascular and pulmonary diseases. Eur Heart J Acute Cardiovasc Care 2016;5:416-433.
76. Rutten FH, Vonken EJ, Cramer MJ, Moons KG, Velthuis BB, Prakken NH, Lammers JW, Grobbee DE, Mali WP, Hoes AW. Cardiovascular magnetic resonance imaging to identify left-sided chronic heart failure in stable patients with chronic obstructive pulmonary disease. Am Heart J 2008;156:506-512.
77. Kelly JP, Mentz RJ, Mebazaa A, Voors AA, Butler J, Roessig L, Fiuzat M, Zannad F, Pitt B, O'Connor CM, et al. Patient selection in heart failure with preserved ejection fraction clinical trials. J Am Coll Cardiol 2015;65:1668-1682.
78. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu A H B, et al.; Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-167.
79. Januzzi JL, Van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, Pinto YM, Richards M. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 2006;27:330-337.
80. Trovato GM, Sperandeo M. Sounds, ultrasounds, and artifacts: which clinical role for lung imaging? Am J Respir Crit Care Med 2013;187:780-781.
81. Shyamsundar M, Attwood B, Keating L, Walden A. Clinical review: the role of ultrasound in estimating extra-vascular lung water. Crit Care 2013;17:237.
82. Hawkins NM, Jhund PS, Simpson CR, Petrie MC, Macdonald MR, Dunn FG, Macintyre K, McMurray J J V. Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. Eur J Heart Fail 2010;12:17-24.
83. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;4: CD003566.
84. Stefan MS, Rothberg MB, Priya A, Pekow PS, Au DH, Lindenauer PK. Association between b-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension. Thorax 2012;67:977-984.
85. Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF, Elsik M, Krum H, Hayward CS. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol 2010;55:1780-1787.
86. Mentz RJ, Wojdyla D, Fiuzat M, Chiswell K, Fonarow GC, O'Connor CM. Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). Am J Cardiol 2013;111:582-587.
87. Lainscak M, Podbregar M, Kovacic D, Rozman J, Von Haehling S. Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial. Respir Med 2011;105:S44-S49.
88. Kubota Y, Asai K, Furuse E, Nakamura S, Murai K, Tsukada YT, Shimizu W. Impact of b-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2015;10:515-523.
89. Creagh-Brown B. Benefits of β blockers in chronic obstructive pulmonary disease and heart failure. BMJ 2014;348:g3316.
90. De Miguel Díez J, Chancafe Morgan J, Jiménez García R. The association between COPD and heart failure risk: a review. Int J Chron Obstruct Pulmon Dis 2013;8:305-312.
91. Ekström MP, Hermansson AB, Ström KE. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187:715-720.
92. Böhm M, Robertson M, Ford I, Borer JS, Komajda M, Kindermann I, Maack C, Lainscak M, Swedberg K, Tavazzi L. Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial). Am J Cardiol 2015;116:1890-1897.
93. Lahousse L, Verhamme KM, Stricker BH, Brusselle GG. Cardiac effects of current treatments of chronic obstructive pulmonary disease. Lancet Respir Med 2016;4:149-164.
94. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of betaadrenergic signaling in heart failure? Circ Res 2003;93:896-906.
95. Gershon A, Croxford R, Calzavara A, To T, Stanbrook MB, Upshur R, Stukel TA. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med 2013;173:1175-1185.
96. Au DH, Udris EM, Curtis JR, McDonell MB, Fihn SD; ACQUIP Investigators. Association between chronic heart failure and inhaled beta-2-adrenoceptor agonists. Am Heart J 2004;148:915-920.
97. Au DH, Udris EM, Fan VS, Curtis JR, McDonell MB, Fihn SD. Risk of mortality and heart failure exacerbations associated with inhaled beta-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest 2003;123:1964-1969.
98. Dong Y-H, Chang C-H, Gagne JJ, Hsu C-L, Lai M-S. Comparative cardiovascular and cerebrovascular safety of inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a population-based cohort study. Pharmacotherapy 2016;36:26-37.
99. Bermingham M, O'Callaghan E, Dawkins I, Miwa S, Samsudin S, McDonald K, Ledwidge M. Are beta2-agonists responsible for increased mortality in heart failure? Eur J Heart Fail 2011;13:885-891.
100. Anthonisen NR, Connett JE, Enright PL, Manfreda J; Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002;166:333-339.
101. Ogale SS, Lee TA, Au DH, Boudreau DM, Sullivan SD. Cardiovascular events associated with ipratropium bromide in COPD. Chest 2010;137:13-19.
102. ® trial. Respir Res 2015;16:65.
103. Verhamme K M C, Afonso A S M, Van Noord C, Haag MD, Koudstaal PJ, Brusselle G G O, Sturkenboom M C JM. Tiotropium Handihaler and the risk of cardio- or cerebrovascular events and mortality in patients with COPD. Pulm Pharmacol Ther 2012;25:19-26.
104. D'Urzo AD, Kerwin EM, Chapman KR, Decramer M, DiGiovanni R, D'Andrea P, Hu H, Goyal P, Altman P. Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data. Int J Chron Obstruct Pulmon Dis 2015;10:1599-1612.
105. Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF; ACCORD I study investigators. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 2012;9:90-101.
106. Trivedi R, Richard N, Mehta R, Church A. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. Eur Respir J 2014;43:72-81.
107. [Published erratum appears in Eur Respir J 44:555.]
108. Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators. Indacaterol-glycopyrronium versus salmeterolfluticasone for COPD. N Engl J Med 2016;374:2222-2234.
109. Calzetta L, Rogliani P, Matera MG, Cazzola M. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest 2016;149:1181-1196.
110. White WB, Cooke GE, Kowey PR, Calverley P M A, Bredenbröker D, Goehring U-M, Zhu H, Lakkis H, Mosberg H, Rowe P, et al. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest 2013;144:758-765.
111. Macie C, Wooldrage K, Manfreda J, Anthonisen N. Cardiovascular morbidity and the use of inhaled bronchodilators. Int J Chron Obstruct Pulmon Dis 2008;3:163-169.
112. Macie C, Wooldrage K, Manfreda J, Anthonisen NR. Inhaled corticosteroids and mortality in COPD. Chest 2006;130:640-646.
113. Vestbo J, Anderson JA, Brook RD, Calverley P M A, Celli BR, Crim C, Martinez F, Yates J, Newby DE. SUMMIT Investigators. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a doubleblind randomised controlled trial. Lancet Lond Engl 2016;387:1817-1826.
114. Jara M, Lanes SF, Wentworth C III, May C, Kesten S. Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database. Drug Saf 2007;30:1151-1160.
115. Grau M, Barr RG, Lima JA, Hoffman EA, Bluemke DA, Carr JJ, Chahal H, Enright PL, Jain A, Prince MR, et al. Percent emphysema and right ventricular structure and function: the Multi-Ethnic Study of Atherosclerosis-Lung and Multi-Ethnic Study of Atherosclerosis-Right Ventricle Studies. Chest 2013;144:136-144.
116. Rubin LJ. Cor pulmonale revisited. J Am Coll Cardiol 2013;62:1112-1113.
117. Weitzenblum E. Chronic cor pulmonale. Heart 2003;89:225-230.
118. Hurdman J, Condliffe R, Elliot CA, Swift A, Rajaram S, Davies C, Hill C, Hamilton N, Armstrong IJ, Billings C, et al. Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J 2013;41:1292-1301.
119. Vonk-Noordegraaf A, Marcus JT, Holverda S, Roseboom B, Postmus PE. Early changes of cardiac structure and function in COPD patients with mild hypoxemia. Chest 2005;127:1898-1903.
120. Kawut SM, Poor HD, Parikh MA, Hueper K, Smith BM, Bluemke DA, Lima J A C, Prince MR, Hoffman EA, Austin J H M, et al. Cor pulmonale parvus in chronic obstructive pulmonary disease and emphysema: the MESA COPD study. J Am Coll Cardiol 2014;64:2000-2009.
121. Freixa X, Portillo K, Paré C, Garcia-Aymerich J, Gomez FP, Benet M, Roca J, Farrero E, Ferrer J, Fernandez-Palomeque C, et al.; PACCOPD Study Investigators. Echocardiographic abnormalities in patients with COPD at their first hospital admission. Eur Respir J 2013;41:784-791.
122. Dournes G, Laurent F, Coste F, Dromer C, Blanchard E, Picard F, Baldacci F, Montaudon M, Girodet P-O, Marthan R, et al. Computed tomographic measurement of airway remodeling and emphysema in advanced chronic obstructive pulmonary disease: correlation with pulmonary hypertension. Am J Respir Crit Care Med 2015;191:63-70.
123. Solidoro P, Patrucco F, Bonato R, Boffini M, Libertucci D, Ricci D, Allara E, Rinaldi M, Bucca C. Pulmonary hypertension in chronic obstructive pulmonary disease and pulmonary fibrosis: prevalence and hemodynamic differences in lung transplant recipients at transplant center's referral time. Transplant Proc 2015;47:2161-2165.
124. Goudie AR, Lipworth BJ, Hopkinson PJ, Wei L, Struthers AD. Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med 2014;2:293-300.
125. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Thygesen K, Alpert JS, White HD, Jaffe AS, et al.; Joint ESC/ACCF/AHA/WHF Task Force for Universal Definition of Myocardial Infarction; Authors/Task Force Members Chairpersons; Biomarker Subcommittee; ECG Subcommittee; Imaging Subcommittee; Classification Subcommittee; Intervention Subcommittee; Trials & Registries Subcommittee; Trials & Registries Subcommittee; Trials & Registries Subcommittee; Trials & Registries Subcommittee; ESC Committee for Practice Guidelines (CPG); Document Reviewers. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012;60:1581-1598.
126. Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, et al.; Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016;37:267-315.
127. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, et al.; Task Force Members; ESC Committee for Practice Guidelines; Document Reviewers. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34:2949-3003.
128. Reed RM, Eberlein M, Girgis RE, Hashmi S, Iacono A, Jones S, Netzer G, Scharf S. Coronary artery disease is under-diagnosed and under-treated in advanced lung disease. Am J Med 2012;125:1228. e13-1228.e22.
129. Arnett DK, Goodman RA, Halperin JL, Anderson JL, Parekh AK, Zoghbi WA. AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and US Department of Health and Human Services. Circulation 2014;130:1662-1667.
130. Soriano JB, Rigo F, Guerrero D, Yanez A, Forteza JF, Frontera G, Togores B, Agustí A. High prevalence of undiagnosed airflow limitation in patients with cardiovascular disease. Chest 2010;137:333-340.
131. Franssen F M E, Soriano JB, Roche N, Bloomfield PH, Brusselle G, Fabbri LM, García-Rio F, Kearney MT, Kwon N, Lundbäck B, et al. Lung Function Abnormalities in Smokers With Ischemic Heart Disease. Am J Respir Crit Care Med 2016;194:568-576.
132. Enriquez JR, Parikh SV, Selzer F, Jacobs AK, Marroquin O, Mulukutla S, Srinivas V, Holper EM. Increased adverse events after percutaneous coronary intervention in patients with COPD: insights from the National Heart, Lung, and Blood Institute dynamic registry. Chest 2011;140:604-610.
133. Almagro P, Lapuente A, Pareja J, Yun S, GarciaME, Padilla F, Heredia JL, De La Sierra A, Soriano JB. Underdiagnosis and prognosis of chronic obstructive pulmonary disease after percutaneous coronary intervention: a prospective study. Int J Chron Obstruct Pulmon Dis 2015;10:1353-1361.
134. Andell P, Koul S, Martinsson A, Sundström J, Jernberg T, Smith JG, James S, Lindahl B, Erlinge D. Impact of chronic obstructive pulmonary disease on morbidity and mortality after myocardial infarction. Open Heart 2014;1:e000002.
135. Čulić V. Atypical presentation and unrecognized myocardial infarction. Eur Heart J 2006;27:2607.
136. De Torbal A, Boersma E, Kors JA, Van Herpen G, Deckers JW, Van Der Kuip D A M, Stricker BH, Hofman A, Witteman J C M. Incidence of recognized and unrecognized myocardial infarction in men and women aged 55 and older: the Rotterdam Study. Eur Heart J 2006;27:729-736.
137. Rodríguez L A G, Wallander M-A, Martín-Merino E, Johansson S. Heart failure, myocardial infarction, lung cancer and death in COPD patients: a UK primary care study. Respir Med 2010;104:1691-1699.
138. Patel A R C, Donaldson GC, Mackay AJ, Wedzicha JA, Hurst JR. The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD. Chest 2012;141:851-857.
139. Terzano C, Conti V, Di Stefano F, Petroianni A, Ceccarelli D, Graziani E, Mariotta S, Ricci A, Vitarelli A, Puglisi G, et al. Comorbidity, hospitalization, and mortality in COPD: results from a longitudinal study. Lung 2010;188:321-329.
140. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA; TORCH Clinical Endpoint Committee. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007;62:411-415.
141. Celli BR. Predictors of mortality in COPD. Respir Med 2010;104:773-779.
142. Campo G, Pavasini R, Malagù M, Mascetti S, Biscaglia S, Ceconi C, Papi A, Contoli M. Chronic obstructive pulmonary disease and ischemic heart disease comorbidity: overview of mechanisms and clinical management. Cardiovasc Drugs Ther 2015;29:147-157.
143. Roca M, Verduri A, Corbetta L, Clini E, Fabbri LM, Beghé B. Mechanisms of acute exacerbation of respiratory symptoms in chronic obstructive pulmonary disease. Eur J Clin Invest 2013;43:510-521.
144. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010;137:1091-1097.
145. Behar S, Panosh A, Reicher-Reiss H, Zion M, Schlesinger Z, Goldbourt U; SPRINT Study Group. Prevalence and prognosis of chronic obstructive pulmonary disease among 5, 839 consecutive patients with acute myocardial infarction. Am J Med 1992;93:637-641.
146. Salisbury AC, Reid KJ, Spertus JA. Impact of chronic obstructive pulmonary disease on post-myocardial infarction outcomes. Am J Cardiol 2007;99:636-641.
147. Cooper BG. An update on contraindications for lung function testing. Thorax 2011;66:714-723.
148. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743-753.
149. Neukamm A M C, Høiseth AD, Hagve T-A, Søyseth V, Omland T. Highsensitivity cardiac troponin T levels are increased in stable COPD. Heart 2013;99:382-387.
150. Hattori K, Ishii T, Motegi T, Kusunoki Y, Gemma A, Kida K. Relationship between serum cardiac troponin T level and cardiopulmonary function in stable chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2015;10:309-320.
151. Vanfleteren L E GW, Franssen F M E, Uszko-Lencer N H MK, Spruit MA, Celis M, Gorgels AP, Wouters E F M. Frequency and relevance of ischemic electrocardiographic findings in patients with chronic obstructive pulmonary disease. Am J Cardiol 2011;108:1669-1674.
152. Chang CL, Robinson SC, Mills GD, Sullivan GD, Karalus NC, McLachlan JD, Hancox RJ. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax 2011;66:764-768.
153. Pavasini R, D'Ascenzo F, Campo G, Biscaglia S, Ferri A, Contoli M, Papi A, Ceconi C, Ferrari R. Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: systematic review and meta-analysis. Int J Cardiol 2015;191:187-193.
154. Lee HM, Lee J, Lee K, Luo Y, Sin DD, Wong ND. Relation between COPD severity and global cardiovascular risk in US adults. Chest 2012;142:1118-1125.
155. Schroeder EB, Welch VL, Couper D, Nieto FJ, Liao D, Rosamond WD, Heiss G. Lung function and incident coronary heart disease: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 2003;158:1171-1181.
156. Sin DD, Wu L, Man S F P. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005;127:1952-1959.
157. Lee HM, Liu MA, Barrett-Connor E, Wong ND. Association of lung function with coronary heart disease and cardiovascular disease outcomes in elderly: the Rancho Bernardo study. Respir Med 2014;108:1779-1785.
158. Dursunoglu N, Dursunoglu D, Yildiz Aİ, Uludag B, Alaçam ZN, Sariçopur A. Severity of coronary atherosclerosis in patients with COPD. Clin Respir J [online ahead of print] 25 Nov. 2015; DOI: 10.1111/crj.12412.
159. Battaglia S, Basile M, Scichilone N, Bellia V. Prevalence of co-morbidities and severity of COPD. COPD 2015;12:390-394.
160. Williams MC, Murchison JT, Edwards LD, Agustí A, Bakke P, Calverley P M A, Celli B, Coxson HO, Crim C, Lomas DA, et al.; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax 2014;69:718-723.
161. Ko F W S, Yan BP, Lam YY, Chu J H Y, Chan K-P, Hui D S C. Undiagnosed airflow limitation is common in patients with coronary artery disease and associated with cardiac stress. Respirology 2016;21:137-142.
162. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, et al.; ACC/AHA Task Force Members; Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;130:2354-2394.
163. [Published erratum appears in Circulation 130:e431-432.]
164. Criner GJ, Connett JE, Aaron SD, Albert RK, Bailey WC, Casaburi R, Cooper J A D Jr, Curtis JL, Dransfield MT, Han MK, et al.; COPD Clinical Research Network; Canadian Institutes of Health Research. Simvastatin for the prevention of exacerbations in moderate-tosevere COPD. N Engl J Med 2014;370:2201-2210.
165. Quint JK, Herrett E, Bhaskaran K, Timmis A, Hemingway H, Wedzicha JA, Smeeth L. Effect of β blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records. BMJ 2013;347:f6650.
166. De Miguel-Díez J, Jiménez-García R, Hernández-Barrera V, Carrasco-Garrido P, Bueno H, Puente-Maestu L, Jimenez-Trujillo I, Alvaro-Meca A, Esteban-Hernandez J, De Andrés AL. Time trends in coronary revascularization procedures among people with COPD: analysis of the Spanish national hospital discharge data (2001-2011). Int J Chron Obstruct Pulmon Dis 2015;10:2285-2294.
167. Wu C, Camacho FT, King SB III, Walford G, Holmes DR Jr, Stamato NJ, Berger PB, Sharma S, Curtis JP, Venditti FJ, et al. Risk stratification for long-term mortality after percutaneous coronary intervention. Circ Cardiovasc Interv 2014;7:80-87.
168. Chalmers J, Pullan M, Fabri B, McShane J, Shaw M, Mediratta N, Poullis M. Validation of EuroSCORE II in a modern cohort of patients undergoing cardiac surgery. Eur J Cardiothorac Surg 2013;43:688-694.
169. Saleh HZ, Mohan K, Shaw M, Al-Rawi O, Elsayed H, Walshaw M, Chalmers J A C, Fabri BM. Impact of chronic obstructive pulmonary disease severity on surgical outcomes in patients undergoing nonemergent coronary artery bypass grafting. Eur J Cardiothorac Surg 2012;42:108-113, discussion 113.
170. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-1554.
171. Wedzicha JA, Calverley P M A, Seemungal TA, Hagan G, Ansari Z, Stockley RA; INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26.
172. Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, Deal BJ, Estes N A M III, Field ME, Goldberger ZD, Hammill SC, et al.; Evidence Review Committee Chair†. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 2016;133:e471-e505.
173. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland J, Joseph C, Conti JB, Ellinor PT, Ezekowitz MD, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014;64:2246-2280.
174. Bhatt SP, Dransfield MT. Chronic obstructive pulmonary disease and cardiovascular disease. Transl Res 2013;162:237-251.
175. Goudis CA, Konstantinidis AK, Ntalas IV, Korantzopoulos P. Electrocardiographic abnormalities and cardiac arrhythmias in chronic obstructive pulmonary disease. Int J Cardiol 2015;199:264-273.
176. Divo M, Cote C, De Torres JP, Casanova C, Marin JM, Pinto-Plata V, Zulueta J, Cabrera C, Zagaceta J, Hunninghake G, et al.; BODE Collaborative Group. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186:155-161.
177. Buch P, Friberg J, Scharling H, Lange P, Prescott E. Reduced lung function and risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J 2003;21:1012-1016.
178. Knuiman M, Briffa T, Divitini M, Chew D, Eikelboom J, McQuillan B, Hung J. A cohort study examination of established and emerging risk factors for atrial fibrillation: the Busselton Health Study. Eur J Epidemiol 2014;29:181-190.
179. Barrett TW, Self WH, Jenkins CA, Storrow AB, Heavrin BS, McNaughton CD, Collins SP, Goldberger JJ. Predictors of regional variations in hospitalizations following emergency department visits for atrial fibrillation. Am J Cardiol 2013;112:1410-1416.
180. De Vos CB, Pisters R, Nieuwlaat R, Prins MH, Tieleman RG, Coelen R-JS, Van Den Heijkant AC, Allessie MA, Crijns H J GM. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol 2010;55:725-731.
181. Pisters R, Nieuwlaat R, Prins MH, Le Heuzey JY, Maggioni AP, Camm AJ, Crijns H J GM; Euro Heart Survey Investigators. Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the Euro Heart Survey. Europace 2012;14:666-674.
182. Gu J, Liu X, Tan H, Zhou L, Jiang W, Wang Y, Liu Y, Gu J. Impact of chronic obstructive pulmonary disease on procedural outcomes and quality of life in patients with atrial fibrillation undergoing catheter ablation. J Cardiovasc Electrophysiol 2013;24:148-154.
183. Terzano C, Romani S, Conti V, Paone G, Oriolo F, Vitarelli A. Atrial fibrillation in the acute, hypercapnic exacerbations of COPD. Eur Rev Med Pharmacol Sci 2014;18:2908-2917.
184. Miyazaki M, Nakamura H, Chubachi S, Sasaki M, Haraguchi M, Yoshida S, Tsuduki K, Shirahata T, Takahashi S, Minematsu N, et al.; Keio COPD Comorbidity Research (K-CCR) Group. Analysis of comorbid factors that increase the COPD assessment test scores. Respir Res 2014;15:13.
185. Atzema CL, Lam K, Young C, Kester-Greene N. Patients with atrial fibrillation and an alternative primary diagnosis in the emergency department: a description of their characteristics and outcomes. Acad Emerg Med 2013;20:193-199.
186. Steer J, Gibson J, Bourke SC. The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax 2012;67:970-976.
187. Ekström MP, Jogréus C, Ström KE. Comorbidity and sex-related differences in mortality in oxygen-dependent chronic obstructive pulmonary disease. Plos One 2012;7:e35806.
188. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; ESC Committee for Practice Guidelines. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-2747.
189. [Published errata appear in Eur Heart J 34:790
190. and Eur Heart J 34:2850-2851.]
191. Tükek T, Yildiz P, Akkaya V, Karan MA, Atilgan D, Yilmaz V, Korkut F. Factors associated with the development of atrial fibrillation in patients with COPD: the role of P-wave dispersion. Ann Noninvasive Electrocardiol 2002;7:222-227.
192. Grond M, Jauss M, Hamann G, Stark E, Veltkamp R, Nabavi D, Horn M, Weimar C, Köhrmann M, Wachter R, et al. Improved detection of silent atrial fibrillation using 72-hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. Stroke 2013;44:3357-3364.
193. Sanna T, Diener H-C, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, Rymer MM, Thijs V, Rogers T, Beckers F, et al.; CRYSTAL AF Investigators. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 2014;370:2478-2486.
194. Wilson BD, Clarkson CE, Lippmann ML. Amiodarone-induced pulmonary inflammation. Correlation with drug dose and lung levels of drug, metabolite, and phospholipid. Am Rev Respir Dis 1991;143:1110-1114.
195. Martin WJ II, Rosenow EC III. Amiodarone pulmonary toxicity: recognition and pathogenesis (Part 2). Chest 1988;93:1242-1248.
196. Jackevicius CA, Tom A, Essebag V, Eisenberg MJ, Rahme E, Tu JV, Humphries K, Behlouli H, Pilote L. Population-level incidence and risk factors for pulmonary toxicity associated with amiodarone. Am J Cardiol 2011;108:705-710.
197. Du Q, Sun Y, Ding N, Lu L, Chen Y. Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies. Plos One 2014;9:e113048.
198. Bhatt SP, Wells JM, Kinney GL, Washko GR Jr, Budoff M, Kim Y-I, Bailey WC, Nath H, Hokanson JE, Silverman EK, et al.; COPDGene Investigators. β-Blockers are associated with a reduction in COPD exacerbations. Thorax 2016;71:8-14.
199. Morales DR, Jackson C, Lipworth BJ, Donnan PT, Guthrie B. Adverse respiratory effect of acute b-blocker exposure in asthma: a systematic review and meta-analysis of randomized controlled trials. Chest 2014;145:779-786.
200. Ni Y, Shi G, Wan H. Use of cardioselective b-blockers in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized, placebo-controlled, blinded trials. J Int Med Res 2012;40:2051-2065.
201. Mainguy V, Girard D, Maltais F, Saey D, Milot J, Sénéchal M, Poirier P, Provencher S. Effect of bisoprolol on respiratory function and exercise capacity in chronic obstructive pulmonary disease. Am J Cardiol 2012;110:258-263.
202. Chiang C-E, Naditch-Brûlé L, Murin J, Goethals M, Inoue H, O'Neill J, Silva-Cardoso J, Zharinov O, Gamra H, Alam S, et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol 2012;5:632-639.
203. Lane DA, Lip G Y H. Use of the CHA (2) DS (2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation 2012;126:860-865.
204. Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. Chest 2012;142:305-311.
205. Singh S, Loke YK, Enright P, Furberg CD. Republished: proarrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Postgrad Med J 2014;90:205-207.
206. Wise RA, Anzueto A, Cotton D, Dahl R, Devins T, Disse B, Dusser D, Joseph E, Kattenbeck S, Koenen-Bergmann M, et al.; TIOSPIR Investigators. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 2013;369:1491-1501.
207. Calverley P M A, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Crim C, Willits LR, Yates JC, Vestbo J; TORCH Investigators. Cardiovascular events in patients with COPD: TORCH study results. Thorax 2010;65:719-725.
208. Hohlfeld JM, Furtwaengler A, Könen-Bergmann M, Wallenstein G, Walter B, Bateman ED. Cardiac safety of tiotropium in patients with COPD: a combined analysis of Holter-ECG data from four randomised clinical trials. Int J Clin Pract 2015;69:72-80.
209. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004;125:2309-2321.
210. Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. Bronchodilator use and the risk of arrhythmia in COPD: part 1: Saskatchewan cohort study. Chest 2012;142:298-304.
211. Sessler CN, Cohen MD. Cardiac arrhythmias during theophylline toxicity: a prospective continuous electrocardiographic study. Chest 1990;98:672-678.
212. Ohta K, Fukuchi Y, Grouse L, Mizutani R, Rabe KF, Rennard SI, Zhong N-S. A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD. Respir Med 2004;98:1016-1024.
213. Mann DL, Zipes DP, Libby P, Bonow RO. Braunwald's heart disease: a textbook of cardiovascular medicine. Philadelphia: Elsevier Health Sciences; 2014.
214. Vermond RA, Geelhoed B, Verweij N, Tieleman RG, Van Der Harst P, Hillege HL, Van Gilst WH, Van Gelder IC, Rienstra M. Incidence of atrial fibrillation and relationship with cardiovascular events, heart failure, and mortality: a community-based study from the Netherlands. J Am Coll Cardiol 2015;66:1000-1007.
215. Zarrinkoub R, Wettermark B, Wändell P, Mejhert M, Szulkin R, Ljunggren G, Kahan T. The epidemiology of heart failure, based on data for 2.1 million inhabitants in Sweden. Eur J Heart Fail 2013;15:995-1002.
216. Lubitz SA, Yin X, Rienstra M, Schnabel RB, Walkey AJ, Magnani JW, Rahman F, McManus DD, Tadros TM, Levy D, et al. Long-term outcomes of secondary atrial fibrillation in the community: the Framingham Heart Study. Circulation 2015;131:1648-1655.
217. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney M-T, Corrà U, Cosyns B, Deaton C, et al.; Authors/Task Force Members. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37:2315-2381.
218. Jacobs DR Jr, Kalhan R. Healthy diets and lung health: connecting the dots. Ann Am Thorac Soc 2016;13:588-590.
219. Barnes PJ. Mechanisms of development of multimorbidity in the elderly. Eur Respir J 2015;45:790-806.
220. Casaburi R, ZuWallack R. Pulmonary rehabilitation for management of chronic obstructive pulmonary disease. N Engl J Med 2009;360:1329-1335.
221. Gloeckl R, Marinov B, Pitta F. Practical recommendations for exercise training in patients with COPD. Eur Respir Rev 2013;22:178-186.
222. Franssen F M E, Rochester CL. Comorbidities in patients with COPD and pulmonary rehabilitation: do they matter? Eur Respir Rev 2014;23:131-141.
223. Vanfleteren L E GW, Spruit MA, Groenen M T J, Bruijnzeel P L B, Taib Z, Rutten E P A, Op 't Roodt J, Akkermans MA, Wouters E F M, Franssen F M E. Arterial stiffness in patients with COPD: the role of systemic inflammation and the effects of pulmonary rehabilitation. Eur Respir J 2014;43:1306-1315.
224. Kwan G, Balady GJ. Cardiac rehabilitation 2012: advancing the field through emerging science. Circulation 2012;125:e369-e373.
225. Ades PA, Keteyian SJ, Balady GJ, Houston-Miller N, Kitzman DW, Mancini DM, Rich MW. Cardiac rehabilitation exercise and self-care for chronic heart failure. JACC Heart Fail 2013;1:540-547.
226. Salzwedel A, Nosper M, Röhrig B, Linck-Eleftheriadis S, Strandt G, Völler H. Outcome quality of in-patient cardiac rehabilitation in elderly patients-identification of relevant parameters. Eur J Prev Cardiol 2014;21:172-180.
227. Evans RA, Singh SJ, Collier R, Loke I, Steiner MC, Morgan M D L. Generic, symptom based, exercise rehabilitation: integrating patients with COPD and heart failure. Respir Med 2010;104:1473-1481.
228. Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, Carone M, Celli B, Engelen M, Fahy B, et al.; ATS/ERS Pulmonary Rehabilitation Writing Committee. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006;173:1390-1413.
229. Higginson IJ, Bausewein C, Reilly CC, Gao W, Gysels M, Dzingina M, McCrone P, Booth S, Jolley CJ, Moxham J. An integrated palliative and respiratory care service for patients with advanced disease and refractory breathlessness: a randomised controlled trial. Lancet Respir Med 2014;2:979-987.
230. Beghé B, Verduri A, Roca M, Fabbri LM. Exacerbation of respiratory symptoms in COPD patients may not be exacerbations of COPD. Eur Respir J 2013;41:993-995.